On the other hand, given that MEK1 in EVs may only partially explain the beneficial effect of MEK1 overexpression, further studies on downstream gene expression changes in 9609‐MEK1 versus 9609‐GFP could elucidate other mechanisms by which the tumour suppressor MEK1 might counterintuitively activate the immune system. The gene discussed is MAP2K1; the disease is neoplasm.